Mammalian base excision repair (BER) is mediated through at least two subpathways designated 'single-nucleotide' (SN) and 'long-patch' (LP) BER (2-nucleotides long/more repair patch). Two forms of DNA substrate are generally used for in vitro BER assays: oligonucleotide-and plasmid-based. For plasmid-based BER assays, the availability of large quantities of substrate DNA with a specific lesion remains the limiting factor. Using sequence-specific endonucleases that cleave only one strand of DNA on a double-stranded DNA substrate, we prepared large quantities of plasmid DNA with a specific lesion. We compared the kinetic features of BER using plasmid and oligonucleotide substrates containing the same lesion and strategic restriction sites around the lesion. The K m for plasmid DNA substrate was slightly higher than that for the oligonucleotide substrate, while the V max of BER product formation for the plasmid and oligonucleotide substrates was similar. The catalytic efficiency of BER with the oligonucleotide substrate was slightly higher than that with the plasmid substrate. We conclude that there were no significant differences in the catalytic efficiency of in vitro BER measured with plasmid and oligonucleotide substrates. Analysis of the ratio of SN BER to LP BER was addressed using cellular extracts and a novel plasmid substrate.
INTRODUCTION
To understand cellular responses to endogenous genotoxic stress, it is important to have insight into the DNA repair process known as base excision repair (BER). BER is involved in repairing base lesions and single-strand breaks that occur thousands of times during the average mammalian cell cycle (1) (2) (3) and is generally considered to involve two subpathways defined by the size of the repair patch and the enzymes involved (4-7). These subpathways are termed single-nucleotide (SN) BER and long-patch (LP) BER. As these names imply, in SN BER one nucleotide in the damaged strand is excised and replaced (8) (9) (10) (11) , whereas LP BER excises and replaces several nucleotides in the damaged strand (6, 9) . LP BER appears to be a backup subpathway in cases where the SN BER system stalls or where the DNA lesion is refractory to the enzymatic steps of the SN BER subpathway (6, 9, (12) (13) (14) .
Components of the BER system are constitutively expressed in mammalian cells, but also exhibit widely divergent tissue-specific expression levels plus up-or down-regulation after genotoxic stress and cytokine exposure (15) (16) (17) (18) (19) (20) . This dynamic regulatory picture suggests the potential for cell type specific differences in cellular capacity for BER and also for differences in relative use of the two BER subpathways, since there are distinct enzymes and accessory factors involved in each (4) (5) (6) (7) 10, (21) (22) (23) (24) (25) . Methods for characterization of the overall amount and efficiency of BER in vivo are limited, and improved methods for quantitative measurement of repair capacity and subpathway choice are needed for studies of extract-mediated BER.
In recent years, research in the BER area has been greatly facilitated through measurements of in vitro BER activity using oligonucleotide and plasmid substrates containing a lesion in a defined site and sequence context (4) (5) (6) 8, 10, 26) . There has been debate, however, on advantages and disadvantages regarding the form of DNA used as substrate, i.e. plasmid versus oligonucleotide. For example, oligonucleotide substrates offer the advantage of relative ease of preparation of large amounts of pure material, and hence the option of preparing in vitro reaction mixtures with an excess of DNA substrate. Under this condition, steady-state measurements of repair activity of extracts can be obtained using short incubation periods (e.g. 1 min) and small amounts of protein extract (e.g. 1 mg). On the other hand, use of a plasmid substrate with the same lesion has involved reaction mixtures with only minimal concentrations of substrate DNA, in view of the difficulty of preparing large quantities of plasmid material. This limitation imposes a need for longer incubation periods with higher amounts of protein extract, in order to observe conversion of a significant amount of substrate into product. Such substrate-limiting, or efficiency-based, conditions can complicate interpretation of reaction kinetics. In addition, there are concerns regarding competing enzymatic activities such as nucleases, as well as plasmid substrate impurities that reduce the effective concentration of substrate. Nevertheless, there can be advantages in using plasmid substrate molecules. For example, artifacts due to protein binding to DNA ends can be eliminated. Also plasmids allow assembly of multi-protein complexes that are too large to be accommodated on oligonucleotide molecules. In addition, plasmids enable use of clamp proteins requiring long and/or circular substrate molecules, such as PCNA (23) . Finally, there has been a suggestion that plasmid DNA substrates are more relevant to in vivo events than oligonucleotide substrate molecules, however, this latter point has been controversial.
Resolution of this debate and uncertainties about choice of substrate DNA can be facilitated by a direct comparison of BER kinetics obtained with each type of DNA bearing the same lesion and sequence context. This comparison has been enabled recently by the introduction of a method for plasmid DNA preparation that yields large amounts of purified plasmid in a relatively short period (26) (27) (28) (29) (30) . In the present study, we examined cell extract-mediated uracil-initiated BER using plasmid and oligonucleotide substrates with the U:G mispair in the same sequence context. Repair was measured under steady-state conditions for each type of substrate. Values for K m and V max were obtained using laboratory reference extracts from bovine testis and mouse embryonic fibroblasts (MEF). The results of these analyses indicated that plasmid and oligonucleotide substrates yielded similar V max values for uracil-DNA BER activity, although the catalytic efficiency (V max /K m ) of repair with the oligonucleotide substrate was slightly higher than with the plasmid substrate. Methods for measuring the ratio of the two BER subpathways, SN BER and LP BER, and for evaluation of the LP BER repair patch size are also discussed.
MATERIALS AND METHODS

Materials
Synthetic oligodeoxyribonucleotides were from Integrated DNA Technologies, Inc. (Coralville, IA, USA) and Oligos Etc. Inc. (Wilsonville, OR, USA). The [a- 32 P]dCTP and dTTP (3000 Ci/mmol) were from GE HealthCare (Piscataway, NJ, USA). Pfu DNA polymerase was from Stratagene (La Jolla, CA, USA). Endonuclease N.BstNB1, T4 DNA ligase and all other restriction enzymes were from New England Biolabs (Beverly, MA, USA). Plasmids were isolated using Qiagen Plasmid Maxi kits from Qiagen (Valencia, CA, USA). Streptavidin-coated magnetic beads (Dynabeads M-280) were from Invitrogen (Carlsbad, CA, USA). Recombinant human DNA polymerase b (Pol b) was overexpressed and purified as described previously (31) . Human uracil-DNA glycosylase (UDG), apurinic/ apyrimidinic endonuclease (APE) and DNA ligase I were purified as described previously (32) (33) (34) .
Preparation of lesion-specific plasmid DNA substrates Lesion-specific BER plasmid substrates were prepared essentially as described previously (29) with slight modifications. Plasmid pUC19N was derived from pUC19 by inserting a 43-bp phosphorylated oligonucleotide (5 0 -GATCGAGTCGAATGCATGCCTCGAGTCT A GAGGTACCAGATCT-3 0 ) at the BamHI site position 417. During this process the BamHI site was lost. The resulting pUC19N contained two N.BstNB1 sites flanking 48 bases that could be substituted with a lesion-specific oligonucleotide. The sequence of the pUC19N plasmid was confirmed by sequencing. A 48-mer oligonucleotide in the sense strand that contained a defined lesion base [uracil or tetrahydrofuran (THF) at position 20, underscored C above] was replaced between two N.BstNB1 sites as follows: pUC19N (100 mg, 57 pmol) was digested with 500 U of N.BstNB1 at 558C for 2 to 3 h, followed by subsequent incubation with 200 pmol 3 0 -biotin-tagged complementary 48-mer oligonucleotide on a rotary shaker for 30 min at 378C. Then, streptavidin-coated Dynabeads M-280 (400 pmol), pre-equilibrated with 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA and 1 M NaCl, were added to the reaction mixture, and the mixture was incubated for 2 h at 378C. The 48-bp biotintagged DNA, adsorbed onto magnetic beads, was separated from the gapped-pUC19N DNA by placing the reaction mixture tube on a magnet for 2 min to collect the beads. The supernatant was carefully removed with a pipette while the tube remained on the magnet. Gappedplasmid DNA in the supernatant was extracted twice with phenol/chloroform and precipitated with 95% ethanol. A 20-fold excess of uracil or THF lesion-containing 48-mer oligonucleotide (1.0 nmol) was added to the gapped-pUC19N DNA in 10 mM Tris-HCl, pH 8.0 and 50 mM NaCl. The DNA mixture was annealed at 458C for 4 h, and then incubated at 258C for 15 h with 5000 U of T4 DNA ligase. In order to purify the closed-circular DNA (ccDNA) plasmid from the un-ligated nicked DNA, two rounds of isopycnic centrifugation in CsCl 2 with ethidium bromide were performed. The yield of lesion-specific plasmid DNA was $30-50% of the starting plasmid (i.e. $25 pmol). The purity of each plasmid preparation was evaluated by digestion with XhoI and subsequent electrophoretic separation of ccDNA and linearized DNA. In this assay, the starting plasmid, pUC19N (plasmid without a lesion), was linearized by XhoI digestion, whereas the lesion-specific substrates were not. This test for contaminating starting plasmid was considered an important precaution as contamination with the starting plasmid was found to be significant for some preparations, owing to inefficient removal of 48-mer N.BstNB1 DNA fragment and religation in the last step described above. The resulting plasmids containing either uracil or THF were designated as pUN1 or pUN2, respectively. Routinely, the ratio of lesion-specific plasmid to starting plasmid was greater than 3 : 1 in the experiments shown here.
Preparation of lesion-specific oligonucleotide DNA substrates Unphosphorylated 55-mer oligonucleotide (100 mM) with 3 0 inverted dT (5 0 -TCGGTACCCGGGGATCGAGT CGAATGCATGCCTCGAGTCTAGAGGTACCAGAT CT-3 0 ) containing either uracil or THF at position 32 (underscored C) was annealed to its complementary unphosphorylated 55-mer in 10 mM Tris-HCl, pH 8.0 and 100 mM NaCl, and then the DNA solution was diluted to 1 mM in the same buffer. The solution was divided into aliquots and stored at À808C.
Preparation of lesion-specific pPAL1 plasmid
The plasmid pGL4.10TKÁKpn (5.0 kb) was constructed from pGL4.10 (Promega, Madison, WI, USA) by inserting the TK promoter between KpnI and HindIII sites. During this process the KpnI site was lost. For the in vitro BER plasmid assay, pPAL1 was prepared by replacing the HindIII-ApaI fragment of pGL4.10TKÁKpn with an oligonucleotide that contained a uracil at a new KpnI site and unique NcoI and SacI restriction sites.
To prepare the HindIII-ApaI fragment, pGL4.10TK ÁKpn was digested with ApaI and subsequently treated with calf intestine alkaline phosphatase. The resultant plasmid was digested by HindIII and purified by 1% agarose gel electrophoresis. Then a 73/81-bp hybrid oligonucleotide was prepared by annealing unphosphorylated 73-mer 5 0 CTTCTTAATGTTTTTGGCATCTTCC ATGGTGGCTTTACCAAGGTAUCAGTAAGTATTA ATTAAGGAGAGCTCA-3 0 and 5 0 -phosphorylated 81-mer 5 0 -AGCTTGAGCTCTCCTTAATTAATACTT ACTGGTACCTTGGTAAAGCCACCATGGAAGATG CCAAAAACATTAAGAAGGGCC-3 0 DNA. Ligation of this oligonucleotide into the HindIII-ApaI digestion product of pGL4.10TKÁKpn was carried out as described (35) . The closed circular DNA was separated by 1% low-melting temperature agarose gel electrophoresis containing SYBR Gold nucleic acid gel stain (Invitrogen), and the plasmid was recovered using a gel extraction kit (Qiagen). The resulting plasmid, pPAL1, was obtained in microgram quantities.
Nuclear extract preparation
Nuclear extract was prepared from bovine testis essentially as described previously (36) . Briefly, 100 g of bovine testis was minced in 300 ml buffer A [10 mM Hepes, pH 8.0, 1.5 mM MgCl 2 , 10 mM NaCl, 0.5 mM dithiothreitol (DTT), 10 mM sodium metabisulfite, 0.1 mM 4-(2-aminoethyl)benzenesulfonylfluoride (AEBSF), 1 mM benzamidine, 1 mg/ml leupeptin and 1 mg/ml pepstatin A] and homogenized using four 10 s bursts with a blender at 48C. The homogenate was pelleted by centrifugation at 10 000 Â g for 10 min at 48C. Pellet fraction was resuspended in 150 ml of buffer B (same as buffer A, except it contained 1 M NaCl) and blended using three 5 s bursts. The homogenate was centrifuged at 100 000 Â g for 1 h at 48C. The clear supernatant fraction was brought to 40% saturation by adding solid ammonium sulfate slowly with stirring; stirring was continued for 1 h at 48C. The precipitate was recovered by centrifugation at 14 000 Â g for 20 min at 48C. The pellet fraction was resuspended in 50 ml of buffer C (25 mM Hepes, pH 7.5, 100 mM NaCl, 1 mM DTT, 10 mM sodium metabisulfite, 0.5 mM EDTA, 0.1 mM AEBSF, 1 mM benzamidine, 1 mg/ml leupeptin, 1 mg/ml pepstatin A and 20% glycerol) and dialyzed against the same buffer. The dialyzed nuclear extract was clarified by centrifugation at 10 000 Â g for 20 min. The clear supernatant fraction was referred to as the bovine testis nuclear extract (BTNE) and stored at À808C. Protein concentration was determined with a Bio-Rad protein assay kit using bovine serum albumin (BSA) as a standard.
Cell extract preparation
Whole cell extract was prepared as previously described (4) . Briefly, cells were washed twice with phosphate-buffered saline at room temperature, detached by scraping, pelleted by centrifugation and resuspended in Buffer I (10 mM Tris-HCl, pH 7.8, 200 mM KCl and protease inhibitor cocktail). An equal volume of Buffer II (10 mM Tris-HCl, pH 7.8, 200 mM KCl, 2 mM EDTA, 40% glycerol, 0.2% Nonidet P-40, 2 mM DTT and protease inhibitor cocktail) was added. The suspension was rotated for 1 h at 48C, and the resulting extract was clarified by centrifugation at 14 000 rpm at 48C. The protein concentration of the extract was determined as above, and aliquots were stored at À808C.
In vitro BER assay
Uracil-and THF-containing plasmids were designed as described above to quantify total BER, SN BER and LP BER in the same reaction. A 48-nt N.BstNB1 fragment containing uracil or THF (Figure 1 ) was inserted in pUC19, which upon digestion with strategic restriction enzymes, as indicated in Figure 2 , would generate fragments representing total BER product (41-bp KpnI fragment), SN BER plus LP BER (25-bp KpnI-XhoI fragment) and LP BER (16-bp XhoI-KpnI fragment). BER assays were performed using reaction mixtures of 10 ml final volume that contained 20-500 nM plasmid or oligonucleotide DNA substrate, 10 mg of extract, 50 mM Tris-HCl, pH 7.5, 5 mM MgCl 2 , 20 mM NaCl, 1 mM DTT, 4 mM ATP, 20 mM each of dATP, dGTP and dTTP or dCTP and 2.3 mM [a-32 P]dCTP or [a-32 P]dTTP, as indicated. The incubation was at 378C for 1 to 30 min, as indicated. Reactions were terminated by adding 1 ml of 0.5 M EDTA and 90 ml TE (10 mM TrisHCl, pH 8.0 and 1 mM EDTA), and this was followed by phenol/chloroform extraction and ethanol precipitation. To facilitate ethanol precipitation, 100 ng of carrier tRNA was added to each reaction mixture. The resulting DNA pellet fraction was dissolved in H 2 O and divided into three equal portions. These DNA-containing portions were subjected to restriction enzyme digestion as follows: (i) no enzyme, (ii) KpnI and (iii) KpnI plus XhoI. The reaction mixtures were incubated for 90 min at 378C. The resulting reaction products were separated by 20% denaturing polyacrylamide gel electrophoresis (PAGE). The gels were dried, scanned with a Typhoon PhosphorImager and the data were analyzed with ImageQuant software. The BER assay, with uracilcontaining plasmid, pPAL1, also was performed under similar reaction conditions as above, and the repaired DNA was restricted with NcoI/SacI and/or KpnI, as indicated in Figure 5 . The experiments were repeated several times, and representative images and average values of SN BER and LP BER are shown. In vitro BER assays using the 55-bp oligonucleotide duplex DNA and cellular extracts were performed under similar reaction conditions as with the plasmid DNA.
RESULTS
Preparation of plasmid DNA substrates
A plasmid DNA substrate containing either uracil or THF opposite guanine was prepared as outlined in Figure 1 . Uracil opposite guanine was chosen because this mismatch is a widely used initiating lesion for studies of in vitro BER. The THF abasic site lesion was chosen as a reference because all BER with this lesion occurs through the LP BER subpathway, since DNA ligation after the gap-filling step in BER is blocked by the persistent THF group (12, 13) . A key feature in plasmid preparation was the use of the single-strand cutting restriction enzyme N.BstNB1, such that a single-strand gap of 48 nt was introduced into the plasmid and the released 48-mer was removed (Figure 1, see penultimate step) . Eventually, a synthetic 48-mer uracil-containing or THF-containing oligonucleotide was annealed into the gap, and the nicks were ligated with good yield (Figure 1, final step) . The plasmids (pUN1 or pUN2) thus prepared could be purified in milligram quantities, enabling the use of as much as micromolar final concentrations of plasmid substrate in BER reaction mixtures.
In addition, these plasmids were designed such that the lesion was flanked with two KpnI sites (Figure 2A) . Digestion of BER reaction products with this enzyme yielded a 41-nt fragment (41-mer). Upon denaturing gel electrophoresis, the incorporation of labeled dNMPs into the repair patch within this fragment could be measured. Quantitative assessment of the repair product formed during the BER incubation could be obtained by double digestion with KpnI and XhoI and use of 32 P-labeled dCTP as one of the nucleotide substrates. In this way, incorporation of labeled dCMP into the first dNMP position of the repair patch was used to quantify the molar amount of repair product formed. This digestion also produced a 16-mer fragment corresponding to the second through seventeenth incorporations by the LP BER subpathway, and should contain most of the LP BER product (Figure 2A) . In some cases, KpnI digestion alone yielded a 25-nt (25-mer) labeled fragment reflecting accumulation of stalled/unligated BER intermediate, i.e. intermediate prior to the DNA ligation step in SN BER or the strand displacement step in LP BER. In the experiments shown subsequently, this material was considered as background since it did not represent complete repair. Digestion with other restriction enzymes is also illustrated in Figure 2 . Two fragments are produced by double digestion with XhoI and XbaI, a 6-mer representing the second through seventh incorporations in the repair patch and a 23-mer representing incorporations out to the 30th position in the repair patch (Figure 2A) .
With the oligonucleotide substrates, a related strategy was used for analysis of BER reaction products. These oligonucleotide substrates had lesions and sequences identical to those in the plasmid substrates (Figure 2 ). In the case of products formed in reaction mixtures with labeled dCTP, digestion with XhoI yielded a 32-mer containing the first labeled dCMP incorporated ( Figure 2B ), allowing assessment of the molar amount of product formed. The stalled or unligated BER Figure 1 . Construction of lesion-specific plasmid substrates. Lesionspecific plasmid substrates for in vitro BER assays, pUN1 and pUN2, were constructed as described under 'Materials and Methods section'. The pUC19 was cut with BamHI and a 43-bp fragment was inserted to create pUC19N that contained two N.BstNB1 sites. Then, the pUC19N was digested with N.BstNB1 to generate a 48-nt gap. The 48-nt fragment was removed by hybridization to a biotinylated-tagged complementary oligonucleotide and followed by adsorption onto streptavidincoated magnetic beads. Next, the plasmid, pUN1 or pUN2, was created by re-hybridization and ligation of gapped pUC19N to the 5 0 -phosphorylated 48-mer oligonucleotide containing either uracil or THF, respectively, as shown.
intermediate was observed in some cases, and again, this material was considered as background. The XhoI digestion also yielded a 23-mer fragment containing the LP BER incorporations ( Figure 2B ). Typical results obtained with a laboratory reference tissue extract, BTNE, and the plasmid and oligonucleotide substrates described above are shown in Figure 3 . Repair of the uracil-DNA plasmid substrate and digestion with KpnI resulted in the labeled 41-mer fragment; very little stalled 25-mer intermediate was observed (Figure 3A) . In contrast, with the THF-containing plasmid substrate, a significant band representing the stalled intermediate was observed with KpnI digestion alone ( Figure 3A) . This indicated accumulation of the intermediate at the step just prior to strand displacement synthesis in LP BER. The results obtained with the oligonucleotide substrates without restriction enzyme digestion were similar, except the stalled intermediate was more abundant ( Figure 3B ). Double digestion of the plasmid products yielded the 25-mer and 16-mer fragments described above ( Figure 3C ). The results illustrated that most of the uracil-DNA repair corresponded to SN BER, as expected from earlier results (9) . Analysis of the product formed on the THF-containing oligonucleotide substrate revealed that the amount of stalled intermediate was greater than the LP BER product, and with uracil-DNA the results were similar to those with plasmid substrate ( Figure 3D ).
Comparison of steady-state kinetic features of repair with plasmid and oligonucleotide substrates
The main goal of this study was to compare kinetic features of BER product formation with plasmid and oligonucleotide substrates. We measured the initial rates of BTNE-mediated BER for the two forms of substrate under conditions of substrate excess. The rates of product formation with various uracil-DNA substrate concentrations were linear over the first 10 min of incubation, as illustrated at one substrate concentration in the experiment shown in Figure 4 . Kinetic features for BTNEmediated BER with the two substrates are summarized in Table 1 . The maximal velocities (V max ) of BER product formation for the plasmid and oligonucleotide substrates were similar, but the K m for the plasmid substrate, pUN1, was slightly higher than that for the oligonucleotide substrate. The resultant efficiency (V max /K m ) was slightly higher (3-fold) with the oligonucleotide substrate. These results indicate that similar rates of uracil-DNA repair can be obtained with the two forms of substrate, especially when they are used at concentrations high enough to support near maximal synthesis, i.e. ) K m . 
Use of plasmid substrate in measurement of the ratio of SN to LP BER
In some cases, it is desirable to measure the relative amounts of the SN and LP BER subpathways. Adjusting the sequence of the repair patch to eliminate ambiguity from incorporation of more than one labeled dNMP in each subpathway can facilitate this measurement. To accomplish this type of measurement, we constructed an alternate plasmid substrate termed 'pPAL1' ( Figure 5A ). This plasmid was designed for use in BER assays along with [a-32 P]dCTP as the labeled nucleotide substrate. To illustrate use of this method, incubations were conducted with MEF extract. Double digestion of the reaction product with NcoI and SacI yielded a 47-mer representing the entire excision repair patch and a small amount of stalled intermediate ( Figure 5B ). Digestion with these enzymes plus KpnI yielded a 22-mer with the first dNMP incorporated, labeled dCMP, and a 25-mer with labeled dCMP corresponding to the second nucleotide incorporated and potentially the 25th dCMP incorporated into the repair patch ( Figure 5A ). Since the repair patch in LP BER is shorter than 25 residues, potential dCMP incorporation at the 25th position can be ignored. Therefore, quantification of [a- 32 P]dCMP incorporated into the 22-mer and 25-mer fragments, respectively, yields the molar amounts of total BER product (SN and LP BER) and LP BER product, as illustrated in Figure 5 . In this case, the ratio of SN BER to LP BER was approximately 60:40 ( Figure 5C ), as expected from earlier results obtained by different methods (21, 37) .
Repair patch analysis for long patch base excision repair products
As noted in Figure 2 , the plasmid and oligonucleotide substrates can be used for repair patch size assessment of LP BER reaction products. Such analysis involves restriction enzyme digestion and then the electrophoretic separation and quantification of various labeled fragments ( 32 P-labeled dNMP incorporation). Typical results from this type of analysis are illustrated in Figure 6 . In the experiment shown, we used the THF-containing plasmid, pUN2, (Figure 1 ) so that repair corresponded to the LP BER subpathway only, along with an extract known to be proficient in LP BER (i.e. from MEFs). Measurement of dCMP and dTMP incorporated in separate incubations was conducted (Figure 6 ). In this case for LP BER, the amount of dCMP incorporation into the first dNMP position (i.e. 25-mer) is equal to the amount of dTMP incorporation into the second dNMP position. Therefore, to evaluate LP BER synthesis beyond the second Figure 3 . Comparison of BER reaction products using plasmid and oligonucleotide substrates. In order to compare the BER reaction products using plasmid-based or oligonucleotide-based assay, the repair reaction was performed with lesion-specific DNA substrate, as indicted at the top of each panel, and BTNE. The reaction conditions and product analyses were as described under 'Materials and Methods' section. Panels (A-D), BER reaction was performed in a 10 ml reaction mixture that contained 50 nM plasmid/oligonucleotide DNA (uracil-or THF-containing DNA) and 10 mg BTNE. Incubation was for 30 min at 378C. The reaction products were purified, digested with the indicated restriction enzyme (s), and then separated by 20% denaturing PAGE. Panels (A) and (B) show the total BER products represented by 41-mer and 55-mer DNA fragments obtained with uracil or THF-containing plasmid, pUN1 or pUN2, and oligonucleotide substrates, respectively. The 25-mer and 32-mer DNA fragments observed with plasmid and oligonucleotide substrates, respectively, represented unligated or stalled intermediates. Panels (C) and (D), the remaining reaction products in (A) and (B) were digested with KpnI or KpnI plus XhoI (Panel C), and XhoI (Panel D), respectively. This resulted in 25-mer (SN BER) and 16-mer (LP BER) DNA fragments from plasmid substrate and 32-mer (SN BER) and 23-mer (LP BER) DNA fragments from oligonucleotide substrate, respectively. In cases where unligated or stalled intermediates were observed (i.e. the 25-mer and 32-mer fragments), the counts in these molecules were considered as background and subtracted for the calculation of SN BER. The positions of total BER, SN BER/stalled and LP BER products are indicated.
nucleotide, the amount of dTMP incorporated into the second position of the 16-mer could be subtracted from total dTMP incorporation into the 16-mer; this synthesis in the 16-mer for dTMP incorporation was similar to that for dCMP incorporation ( Figure 6B and C) .
Further analysis of repair patch size is illustrated in Figure 7 . Typical results ( Figure 7A ) and the strategy for analysis using 32 P-labeled dCMP incorporation ( Figure 7B ) were as follows: Restriction with KpnI yielded a 41-nt fragment (41-mer) representing repair patch synthesis, i.e. from one up to 17 nucleotide incorporations ( Figure 7A, lane 1, and B) . With KpnI digestion, some 25-mer BER intermediate was also observed, reflecting stalling at this intermediate. Incorporation of the first nucleotide in the repair patch, dCMP, was measured after double digestion with KpnI and XhoI, yielding the 25-mer and the 16-mer ( Figure 7A lane 2) . The 16-mer fragment reflected three LP BER dCMP incorporations ( Figure 7A , lane 2, and B). For LP BER synthesis at the 2nd through 7th nucleotides and longer repair patches, respectively, we measured dCMP incorporation into the corresponding fragments after double digestions with XhoI and XbaI, i.e. two fragments (6-mer and 23-mer) as illustrated in Figure 7 ( Figure 7A, lane 3, and B) . Incorporation into the 6-mer was greater than that into the 23-mer, indicating that most of the LP BER corresponded to repair patches of 7 nt or less ( Figure 7C ).
DISCUSSION
We made use of a recently acquired method for obtaining large amounts of plasmid DNA after a preparative in vitro ligation step (30) . A plasmid with a single-strand 48 base gap was prepared in high yield and in pure enough form to enable annealing a 48-mer lesion-containing oligonucleotide into the gap. After ligation and purification of the lesion-containing plasmid DNA substrate, a relatively large amount of DNA was available for use in routine BER incubations (Figure 1 ). The availability of such large quantities of plasmid substrate made it possible for us to compare steady-state kinetic values for BER obtained with an oligonucleotide substrate with those obtained with a plasmid substrate. Such a comparison had been unresolved and remained an important consideration. Some investigators maintained that plasmid substrates are more biologically relevant or useful than oligonucleotide substrates. On the other hand, others have held the opposite viewpoint asserting that plasmid substrates are of limited and specialized use because of the necessity to employ miniscule concentrations of substrate DNA and long incubation periods, both of which potentially confound interpretations on BER capacity measurements. Our results indicated that the two forms of substrate yielded similar values for rates of repair in a nuclear extract, provided the DNA substrate concentration was high enough in the reaction mixture.
A precaution emerged from the observation that K m for plasmid substrate was higher than K m for oligonucleotide substrate. An explanation for this difference was not examined. However, on a practical level, when a substrate excess or steady-state approach is used to quantify Table 1 . Steady-state kinetic measurements of BER using plasmid and oligonucleotide substrates Oligonucleotide Plasmid extract-based repair synthesis, the K m difference between the two forms of DNA may need to be taken into account.
In addition to characterizing rates of BER as a function of substrate form, we examined methods for analysis of repair patch length in the LP BER subpathway. Our initial experiments in this effort made use of phosphorothioate dNMP incorporation into the repair patch and subsequent exonuclease III digestion of products [data not shown, and ref. (37) ]. This approach yielded spurious results (data not shown). The main difficulty stemmed from the capacity of exonuclease III to digest into the repair patches containing phosphorothioate dNMPs, leading to an underestimate of repair patch length. On the other hand, attempts to reduce the digestion strategically (time or enzyme concentration) generally lead to an overestimate of repair patch length. Therefore, we concluded that reliable measurements of repair patch length could not be obtained with this approach. The approach described here, however, appeared to be reliable and was limited only by the technical requirements to obtain pure substrate preparations, restriction digestion of product molecules to completion, and attention to accurate quantification of the amount of labeled dNMP incorporated. Figure 6 . The experiments were repeated three times, and the PhosphorImage of a representative experiment is shown.
